Related Experiment Video
Updated: Aug 17, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T
Jing Liu1, Yan-Yan Hu1, Qiu-Yan Zhang2
1Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; University of Chinese Academy of Sciences, Beijing, China.
Abstract:
As an emerging tumor therapy, ideal oncolytic viruses preferentially replicate in malignant cells, reverse the immunosuppressive tumor microenvironment, and eventually can be eliminated by the patient. It is of great significance for cancer treatment to discover new excellent oncolytic viruses. Here, we found that WNV live attenuated vaccine WNV-poly(A) could be developed as a novel ideal oncolytic agent against several types of cancers. Mechanistically, due to its high sensitivity to type Ι interferon (IFN-Ι), WNV-poly(A) could specifically kill tumor cells rather than normal cells. At the same time, WNV-poly(A) could activate Dendritic cells (DCs) and trigger tumor antigen specific response mediated by CD8 + T cell, which contributed to inhibit the propagation of original and distal tumor cells. Like intratumoral injection, intravenous injection with WNV-poly(A) also markedly delays Huh7 hepatic carcinoma (HCC) transplanted tumor progression. Most importantly, in addition to an array of mouse xenograft tumor models, WNV-poly(A) also has a significant inhibitory effect on many different types of patient-derived tumor tissues and HCC patient-derived xenograft (PDX) tumor models. Our studies reveal that WNV-poly(A) is a potent and excellent oncolytic agent against many types of tumors and may have a role in metastatic and recurrent tumors.
Insights
A live attenuated West Nile Virus vaccine (WNV-poly(A)) shows promise as an oncolytic agent. It specifically targets cancer cells, activates immune responses, and inhibits tumor growth in various models, including patient-derived tumors.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Oncolytic viruses are an emerging cancer therapy.
- Ideal oncolytic viruses selectively replicate in cancer cells and modulate the tumor microenvironment.
Purpose of the Study:
- To investigate the potential of WNV live attenuated vaccine (WNV-poly(A)) as an oncolytic agent.
- To elucidate the mechanisms underlying its anti-cancer activity.
Main Methods:
- Testing WNV-poly(A) in various cancer cell lines and mouse xenograft models.
- Evaluating immune responses, including dendritic cell activation and CD8+ T cell activity.
- Assessing efficacy in patient-derived tumor tissues and models.
Main Results:
- WNV-poly(A) selectively replicates in and kills tumor cells due to high sensitivity to type I interferon (IFN-I).
- WNV-poly(A) activates dendritic cells (DCs) and promotes CD8+ T cell-mediated anti-tumor immunity.
- Intravenous and intratumoral administration of WNV-poly(A) significantly inhibited tumor progression in multiple models, including patient-derived xenografts.
Conclusions:
- WNV-poly(A) is a potent oncolytic agent effective against diverse cancer types.
- This agent shows potential for treating primary, metastatic, and recurrent tumors.
- WNV-poly(A) warrants further investigation as a novel cancer therapeutic.
Related Concept Videos
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...